Skip to content

PARTNERING OPPORTUNITIES

Bionomics has a lengthy history of successful alliances with industry and academia. In general, the company seeks to develop compounds to successful proof of concept in human clinical trials. We are open to expressions of interest with respect to partnership at all stages of development.

Additionally, Bionomics is open to in-licensing proposals that are in alignment with the company’s overall therapeutic focus in CNS diseases.

Pre-Clinical CNS Assets

Kv3.1/3.2 Program 

Small molecule Kv3.1 / Kv3.2 potassium ion channels activators for improving cognitive dysfunction and negative symptoms in schizophrenia and other illnesses such as Autism Spectrum Disorder and Alzheimer’s Disease

Nav Program

Small molecule pan Nav (1.7/1.8/1.9) inhibitors for the treatment of chronic pain

Oncology

BNC105

A multi-modal small molecule tubulin polymerization inhibitor has completed four Phase 1 and Phase 2 clinical trials

BNC101

A humanized monoclonal antibody to LGR5, a cancer stem cell receptor has completed Phase 1 clinical trials

For any partnering enquiries, please contact us here

Contact Us